{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T19:59:30Z","timestamp":1783022370144,"version":"3.54.6"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2017,4,26]],"date-time":"2017-04-26T00:00:00Z","timestamp":1493164800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Drug Metab Pharmacokinet"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1007\/s13318-017-0413-2","type":"journal-article","created":{"date-parts":[[2017,4,26]],"date-time":"2017-04-26T16:32:07Z","timestamp":1493224327000},"page":"965-972","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Observation of Clinically Relevant Drug Interaction in Chimeric Mice with Humanized Livers: The Case of Valproic Acid and Carbapenem Antibiotics"],"prefix":"10.1007","volume":"42","author":[{"given":"Eiko","family":"Suzuki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kumiko","family":"Koyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Nakai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryoya","family":"Goda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Kuga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kan","family":"Chiba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,4,26]]},"reference":[{"key":"413_CR1","doi-asserted-by":"crossref","first-page":"475","DOI":"10.3109\/03602532.2014.967866","volume":"46","author":"S Jaiswal","year":"2014","unstructured":"Jaiswal S, Sharma A, Shukla M, Vaghasiya K, Rangaraj N, Lal J. Novel pre-clinical methodologies for pharmacokinetic drug-drug interaction studies: spotlight on \u201chumanized\u201d animal models. Drug Metab Rev. 2014;46:475\u201393.","journal-title":"Drug Metab Rev"},{"key":"413_CR2","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.bbrc.2011.01.042","volume":"405","author":"M Hasegawa","year":"2011","unstructured":"Hasegawa M, Kawai K, Mitsui T, Taniguchi K, Monnai M, Wakui M, Ito M, Suematsu M, Peltz G, Nakamura M, Suemizu H. The reconstituted \u2018humanized liver\u2019 in TK-NOG mice is mature and functional. Biochem Biophys Res Commun. 2011;405:405\u201310.","journal-title":"Biochem Biophys Res Commun"},{"key":"413_CR3","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1517\/17425250903216664","volume":"5","author":"K Yoshizato","year":"2009","unstructured":"Yoshizato K, Tateno C. In vivo modeling of human liver for pharmacological study using humanized mouse. Expert Opin Drug Metab Toxicol. 2009;5:1435\u201346.","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"413_CR4","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1172\/JCI42338","volume":"120","author":"YP Jong De","year":"2010","unstructured":"De Jong YP, Rice CM, Ploss A. New horizons for studying human hepatotropic infections. J Clin Invest. 2010;120:650\u20133.","journal-title":"J Clin Invest"},{"key":"413_CR5","doi-asserted-by":"crossref","first-page":"557","DOI":"10.3109\/00498254.2015.1091113","volume":"46","author":"H Kamimura","year":"2016","unstructured":"Kamimura H, Ito S. Assessment of chimeric mice with humanized livers in new drug development: generation of pharmacokinetics, metabolism and toxicity data for selecting the final candidate compound. Xenobiotica. 2016;46:557\u201369.","journal-title":"Xenobiotica"},{"key":"413_CR6","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.drudis.2015.09.002","volume":"21","author":"N Scheer","year":"2016","unstructured":"Scheer N, Wilson ID. A comparison between genetically humanized and chimeric liver humanized mouse models for studies in drug metabolism and toxicity. Drug Discov Today. 2016;21:250\u201363.","journal-title":"Drug Discov Today"},{"key":"413_CR7","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1124\/jpet.112.198697","volume":"344","author":"T Nishimura","year":"2013","unstructured":"Nishimura T, Hu Y, Wu M, Pham E, Suemizu H, Elazar M, Liu M, Idilman R, Yurdaydin C, Angus P, Stedman C, Murphy B, Glenn J, Nakamura M, Nomura T, Chen Y, Zheng M, Fitch WL, Peltz G. Using chimeric mice with humanized livers to predict human drug metabolism and a drug\u2013drug interaction. J Pharmacol Exp Ther. 2013;344:388\u201396.","journal-title":"J Pharmacol Exp Ther"},{"key":"413_CR8","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1021\/tx400008g","volume":"26","author":"H Yamazaki","year":"2013","unstructured":"Yamazaki H, Suemizu H, Murayama N, Utoh M, Shibata N, Nakamura M, Guengerich FP. In vivo drug interactions of the teratogen thalidomide with midazolam: heterotropic cooperativity of human cytochrome P450 in humanized TK-NOG mice. Chem Res Toxicol. 2013;26:486\u20139.","journal-title":"Chem Res Toxicol"},{"key":"413_CR9","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1093\/jac\/39.2.295","volume":"39","author":"K Nagai","year":"1997","unstructured":"Nagai K, Shimizu T, Togo A, Takeya M, Yokomizo Y, Sakata Y, Matsuishi T, Kato H. Decrease in serum levels of valproic acid during treatment with a new carbapenem, panipenem\/betamipron. J Antimicrob Chemother. 1997;39:295\u20136.","journal-title":"J Antimicrob Chemother"},{"key":"413_CR10","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1093\/jac\/42.4.563","volume":"42","author":"BJ Turck De","year":"1998","unstructured":"De Turck BJ, Diltoer MW, Cornelis PJ, Maes V, Spapen HD, Camu F, Huyghens LP. Lowering of plasma valproic acid concentrations during concomitant therapy with meropenem and amikacin. J Antimicrob Chemother. 1998;42:563\u20134.","journal-title":"J Antimicrob Chemother"},{"key":"413_CR11","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1023\/A:1013046229699","volume":"18","author":"K Yokogawa","year":"2001","unstructured":"Yokogawa K, Iwashita S, Kubota A, Sasaki Y, Ishizaki J, Kawahara M, Matsushita R, Kimura K, Ichimura F, Miyamoto K. Effect of meropenem on disposition kinetics of valproate and its metabolites in rabbits. Pharm Res. 2001;18:1320\u20136.","journal-title":"Pharm Res"},{"key":"413_CR12","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1124\/dmd.104.000661","volume":"32","author":"Y Nakajima","year":"2004","unstructured":"Nakajima Y, Mizobuchi M, Nakamura M, Takagi H, Inagaki H, Kominami G, Koike M, Yamaguchi T. Mechanism of the drug interaction between valproic acid and carbapenem antibiotics in monkeys and rats. Drug Metab Dispos. 2004;32:1383\u201391.","journal-title":"Drug Metab Dispos"},{"key":"413_CR13","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1124\/dmd.110.032938","volume":"38","author":"E Suzuki","year":"2010","unstructured":"Suzuki E, Yamamura N, Ogura Y, Nakai D, Kubota K, Kobayashi N, Miura S, Okazaki O. Identification of valproic acid glucuronide hydrolase as a key enzyme for the interaction of valproic acid with carbapenem antibiotics. Drug Metab Dispos. 2010;38:1538\u201344.","journal-title":"Drug Metab Dispos"},{"key":"413_CR14","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/j.biochi.2005.04.002","volume":"87","author":"J Perrier","year":"2005","unstructured":"Perrier J, Durand A, Giardina T, Puigserver A. Catabolism of intracellular N-terminal acetylated proteins: involvement of acylpeptide hydrolase and acylase. Biochimie. 2005;87:673\u201385.","journal-title":"Biochimie"},{"key":"413_CR15","doi-asserted-by":"crossref","first-page":"15076","DOI":"10.1016\/S0021-9258(17)36576-6","volume":"269","author":"A Scaloni","year":"1994","unstructured":"Scaloni A, Barra D, Jones WM, Manning JM. Human acylpeptide hydrolase. Studies on its thiol groups and mechanism of action. J Biol Chem. 1994;269:15076\u201384.","journal-title":"J Biol Chem"},{"key":"413_CR16","doi-asserted-by":"crossref","first-page":"958","DOI":"10.3109\/00498254.2011.596582","volume":"41","author":"E Suzuki","year":"2011","unstructured":"Suzuki E, Nakai D, Yamamura N, Kobayashi N, Okazaki O, Izumi T. Inhibition mechanism of carbapenem antibiotics on acylpeptide hydrolase, a key enzyme in the interaction with valproic acid. Xenobiotica. 2011;41:958\u201363.","journal-title":"Xenobiotica"},{"issue":"2","key":"413_CR17","doi-asserted-by":"crossref","first-page":"126","DOI":"10.3109\/00498254.2015.1054002","volume":"46","author":"E Suzuki","year":"2016","unstructured":"Suzuki E, Nakai D, Ikenaga H, Fusegawa K, Goda R, Kobayashi N, Kuga H, Izumi T. In vivo inhibition of acylpeptide hydrolase by carbapenem antibiotics causes the decrease of plasma concentration of valproic acid in dogs. Xenobiotica. 2016;46(2):126\u201331.","journal-title":"Xenobiotica"},{"key":"413_CR18","doi-asserted-by":"crossref","first-page":"67","DOI":"10.2165\/00003088-198005010-00002","volume":"5","author":"R Gugler","year":"1980","unstructured":"Gugler R, Von Unruh GE. Clinical pharmacokinetics of valproic acid. Clin Pharmacokinet. 1980;5:67\u201383.","journal-title":"Clin Pharmacokinet"},{"key":"413_CR19","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1124\/dmd.114.061689","volume":"43","author":"H Kamimura","year":"2015","unstructured":"Kamimura H, Ito S, Nozawa K, Nakamura S, Chijiwa H, Nagatsuka S, Kuronuma M, Ohnishi Y, Suemizu H, Ninomiya S. Formation of the accumulative human metabolite and human-specific glutathione conjugate of diclofenac in TK-NOG chimeric mice with humanized livers. Drug Metab Dispos. 2015;43:309\u201316.","journal-title":"Drug Metab Dispos"},{"key":"413_CR20","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.yrtph.2015.03.010","volume":"72","author":"T Miyaguchi","year":"2015","unstructured":"Miyaguchi T, Suemizu H, Shimizu M, Shida S, Nishiyama S, Takano R, Murayama N, Yamazaki H. Human urine and plasma concentrations of bisphenol A extrapolated from pharmacokinetics established in in vivo experiments with chimeric mice with humanized liver and semi-physiological pharmacokinetic modeling. Regul Toxicol Pharmacol. 2015;72:71\u20136.","journal-title":"Regul Toxicol Pharmacol"},{"key":"413_CR21","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/S0090-9556(24)15311-1","volume":"27","author":"N Yamamura","year":"1999","unstructured":"Yamamura N, Imura K, Naganuma H, Nishimura K. Panipenem, a carbapenem antibiotic, enhances the glucuronidation of intravenously administered valproic acid in rats. Drug Metab Dispos. 1999;27:724\u201330.","journal-title":"Drug Metab Dispos"},{"key":"413_CR22","unstructured":"Abbott. Depakene (valproic acid) Prescribing information. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/018081s046_18082s031lbl.pdf . Accessed 13 Apr 2017."},{"key":"413_CR23","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1016\/S0090-9556(24)13678-1","volume":"28","author":"N Yamamura","year":"2000","unstructured":"Yamamura N, Imura-Miyoshi K, Naganuma H. Panipenum, a carbapenem antibiotic, increases the level of hepatic UDP-glucuronic acid in rats. Drug Metab Dispos. 2000;28:1484\u20136.","journal-title":"Drug Metab Dispos"},{"key":"413_CR24","first-page":"121","volume":"29","author":"MG Soars","year":"2001","unstructured":"Soars MG, Riley RJ, Findlay KA, Coffey MJ, Burchell B. Evidence for significant differences in microsomal drug glucuronidation by canine and human liver and kidney. Drug Metab Dispos. 2001;29:121\u20136.","journal-title":"Drug Metab Dispos"},{"issue":"Suppl 1","key":"413_CR25","first-page":"123","volume":"40","author":"Y Sumita","year":"1992","unstructured":"Sumita Y, Nouda H, Tada E, Kohzuki T, Kato M, Okuda T, Fukasawa M. Pharmacokinetics of meropenem, a new carbapenem antibiotic, parenterally administrated to laboratory animals. Jpn J Chemother. 1992;40(Suppl 1):123\u201331.","journal-title":"Jpn J Chemother"},{"key":"413_CR26","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1093\/dnares\/3.1.31","volume":"3","author":"M Mitta","year":"1996","unstructured":"Mitta M, Ohnogi H, Mizutani S, Sakiyama F, Kato I, Tsunasawa S. The nucleotide sequence of human acylamino acid-releasing enzyme. DNA Res. 1996;3:31\u20135.","journal-title":"DNA Res"},{"key":"413_CR27","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1592\/phco.27.8.1202","volume":"27","author":"JL Lunde","year":"2007","unstructured":"Lunde JL, Nelson RE, Storandt HF. Acute seizures in a patient receiving divalproex sodium after starting ertapenem therapy. Pharmacotherapy. 2007;27:1202\u20135.","journal-title":"Pharmacotherapy"},{"key":"413_CR28","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1177\/0091270009334377","volume":"49","author":"S Haroutiunian","year":"2009","unstructured":"Haroutiunian S, Ratz Y, Rabinovich B, Adam M, Hoffman A. Valproic acid plasma concentration decreases in a dose-independent manner following administration of meropenem: a retrospective study. J Clin Pharmacol. 2009;49:1363\u20139.","journal-title":"J Clin Pharmacol"},{"key":"413_CR29","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.pediatrneurol.2013.03.022","volume":"49","author":"FA Taha","year":"2013","unstructured":"Taha FA, Hammond DN, Sheth RD. Seizures from valproate\u2013carbapenem interaction. Pediatr Neurol. 2013;49:279\u201381.","journal-title":"Pediatr Neurol"}],"container-title":["European Journal of Drug Metabolism and Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s13318-017-0413-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13318-017-0413-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13318-017-0413-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T00:36:36Z","timestamp":1750206996000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s13318-017-0413-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4,26]]},"references-count":29,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["413"],"URL":"https:\/\/doi.org\/10.1007\/s13318-017-0413-2","relation":{},"ISSN":["0378-7966","2107-0180"],"issn-type":[{"value":"0378-7966","type":"print"},{"value":"2107-0180","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,4,26]]}}}